Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03 2024 - 3:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced Myriad management will
present at the 42nd Annual J.P. Morgan Healthcare Conference in San
Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST.
The presentation will be available through a live webcast in the
investor relations section of Myriad’s website at
investor.myriad.com. An archived edition of the presentation will
be available later that day.
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2024 to Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Jun 2023 to Jun 2024